From the journal
Tirzepatide Reconstitution: Avoiding AOD-9604 Peptide Aggregation in Dual-Chamber Syringe Systems for VA Alcohol Use Disorder Trials
Tirzepatide and AOD-9604 reconstitution in dual-chamber syringes for VA alcohol use disorder trials demands strict pH control and surfactant use to
Read more →BPC-157 and IGF-1 LR3: pH Optimization for Dual-Injection Stability
Combining BPC-157 and IGF-1 LR3 in one syringe requires a narrow pH range of 5.5-6.0 to prevent rapid degradation. Solvent selection and...
Read more →Tirzepatide with Kisspeptin: Solvent pH and Aggregation Risk
Co-reconstituting tirzepatide with kisspeptin requires careful pH control to avoid aggregation. Analytical data show purity drops below 95% within 48 hours
Read more →